These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12270167)

  • 21. Antagonists selective for estrogen receptor alpha.
    Sun J; Huang YR; Harrington WR; Sheng S; Katzenellenbogen JA; Katzenellenbogen BS
    Endocrinology; 2002 Mar; 143(3):941-7. PubMed ID: 11861516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raloxifene, arterial function and Ockham's razor.
    Vlachopoulos C; Xaplanteris P; Stefanadis C
    Vascul Pharmacol; 2013 Jan; 58(1-2):1-2. PubMed ID: 23164715
    [No Abstract]   [Full Text] [Related]  

  • 23. Playing the old piano: another tune for endocrine therapy?
    Hayes DF
    J Natl Cancer Inst; 2003 Nov; 95(21):1565-7. PubMed ID: 14600082
    [No Abstract]   [Full Text] [Related]  

  • 24. Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists.
    Chesworth R; Zawistoski MP; Lefker BA; Cameron KO; Day RF; Mangano FM; Rosati RL; Colella S; Petersen DN; Brault A; Lu B; Pan LC; Perry P; Ng O; Castleberry TA; Owen TA; Brown TA; Thompson DD; DaSilva-Jardine P
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2729-33. PubMed ID: 15125923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs.
    Chen HY; Kim S; Wu JY; Birzin ET; Chan W; Yang YT; Dahllund J; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2004 May; 14(10):2551-4. PubMed ID: 15109649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.
    Kelly PM; Bright SA; Fayne D; Pollock JK; Zisterer DM; Williams DC; Meegan MJ
    Bioorg Med Chem; 2016 Sep; 24(18):4075-4099. PubMed ID: 27407030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.
    Lv W; Liu J; Skaar TC; Flockhart DA; Cushman M
    J Med Chem; 2015 Mar; 58(6):2623-48. PubMed ID: 25751283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
    Yang C; Xu G; Li J; Wu X; Liu B; Yan X; Wang M; Xie Y
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1505-7. PubMed ID: 15713417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NJK14013, a novel synthetic estrogen receptor-α agonist, exhibits estrogen receptor-independent, tumor cell-specific cytotoxicity.
    Kim HI; Kim T; Kim JE; Lee J; Heo J; Lee NR; Kim NJ; Inn KS
    Int J Oncol; 2015 Jul; 47(1):280-6. PubMed ID: 25964080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen receptor ligands. Part 6: Synthesis and binding affinity of dihydrobenzodithiins.
    Tan Q; Birzin ET; Chan W; Yang YT; Pai LY; Hayes EC; DaSilva CA; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3753-5. PubMed ID: 15203156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of novel m-carborane-containing estrogen receptor partial agonists as SERM candidates.
    Ohta K; Ogawa T; Kaise A; Endo Y
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3213-6. PubMed ID: 26077489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
    Jordan VC
    J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
    [No Abstract]   [Full Text] [Related]  

  • 35. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
    Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
    ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer.
    Gao M; Wang M; Miller KD; Sledge GW; Zheng QH
    Eur J Med Chem; 2008 Oct; 43(10):2211-9. PubMed ID: 18272256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells.
    Morishima S; Shibata MA; Ohmichi M; Otsuki Y
    Med Mol Morphol; 2008 Sep; 41(3):132-8. PubMed ID: 18807138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells.
    Sukocheva OA; Wee C; Ansar A; Hussey DJ; Watson DI
    Dis Esophagus; 2013 Aug; 26(6):628-35. PubMed ID: 23163347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-classical estrogen receptors action on human dermal fibroblasts.
    Tsui KH; Wang PH; Chen CK; Chen YJ; Chiou SH; Sung YJ; Li HY
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):474-8. PubMed ID: 22212320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.